Bayer Push To Lead OTC Space Relies On Distribution, Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Bayer expands its distribution, invests in emerging markets and innovation and acquires strategic bolt-ons in an attempt to replace Johnson & Johnson as the largest global OTC business, executives say. Growth areas include gastrointestinal and cough/cold products, but not Rx-to-OTC switch.